[Efficacy of bronchodilators: searching for objective criteria].
Aguilaniu
B
B
D000280:Administration, Inhalation; D000318:Adrenergic beta-Agonists / Q000008:administration & dosage / Q000627:therapeutic use*; D000420:Albuterol / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use*; D001993:Bronchodilator Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D004417:Dyspnea / Q000503:physiopathology; D015444:Exercise; D005500:Follow-Up Studies; D005652:Functional Residual Capacity; D006801:Humans; D006985:Hyperventilation / Q000503:physiopathology; D010919:Placebos; D010991:Plethysmography; D029424:Pulmonary Disease, Chronic Obstructive / Q000188:drug therapy* / Q000503:physiopathology; D011788:Quality of Life; D012129:Respiratory Function Tests; D000068299:Salmeterol Xinafoate; D013147:Spirometry; D013997:Time Factors; D014109:Total Lung Capacity
D000318:Adrenergic beta-Agonists; D001993:Bronchodilator Agents; D010919:Placebos; D000068299:Salmeterol Xinafoate; D000420:Albuterol
Quels critères objectifs d'efficacité des broncho-dilatateurs?